Search research articles
Contact Us
Filters
Showing results (51-60 of 172) with videos related to
Page
of 18
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 15, 2021
Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events
Jia Luo, Jason A Beattie, Paige Fuentes, et al.
NPJ Precision Oncology
|
July 16, 2024
Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy
Arielle Elkrief, Eder Orlando Méndez-Salazar, Jade Maillou, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
December 23, 2021
Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab
Maria Thor, Annemarie F Shepherd, Isabel Preeshagul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 14, 2018
Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance
Helena A Yu, Ken Suzawa, Emmet Jordan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 27, 2018
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with <i>EGFR</i>-Mutant Lung Cancers
Michael Offin, Hira Rizvi, Megan Tenet, et al.
Science Advances
|
November 23, 2022
Widespread hypertranscription in aggressive human cancers
Matthew Zatzman, Fabio Fuligni, Ryan Ripsman, et al.
Nature Communications
|
July 18, 2017
Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy
Akane Inoue-Yamauchi, Paul S Jeng, Kwanghee Kim, et al.
Journal for Immunotherapy of Cancer
|
February 3, 2024
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors
Sandip P Patel, Teresa Alonso-Gordoa, Susana Banerjee, et al.
Cancer Medicine
|
May 7, 2020
Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab
Narek Shaverdian, Maria Thor, Annemarie F Shepherd, et al.
Cancer Immunology Research
|
July 12, 2018
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
Fernando C Santini, Hira Rizvi, Andrew J Plodkowski, et al.
Page
of 18
Search research articles
Search
Showing results (51-60 of 172) with videos related to
Sort By:
Page
of 18
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 15, 2021
Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events
Jia Luo, Jason A Beattie, Paige Fuentes, et al.
NPJ Precision Oncology
|
July 16, 2024
Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy
Arielle Elkrief, Eder Orlando Méndez-Salazar, Jade Maillou, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
December 23, 2021
Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab
Maria Thor, Annemarie F Shepherd, Isabel Preeshagul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 14, 2018
Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance
Helena A Yu, Ken Suzawa, Emmet Jordan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 27, 2018
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with <i>EGFR</i>-Mutant Lung Cancers
Michael Offin, Hira Rizvi, Megan Tenet, et al.
Science Advances
|
November 23, 2022
Widespread hypertranscription in aggressive human cancers
Matthew Zatzman, Fabio Fuligni, Ryan Ripsman, et al.
Nature Communications
|
July 18, 2017
Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy
Akane Inoue-Yamauchi, Paul S Jeng, Kwanghee Kim, et al.
Journal for Immunotherapy of Cancer
|
February 3, 2024
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors
Sandip P Patel, Teresa Alonso-Gordoa, Susana Banerjee, et al.
Cancer Medicine
|
May 7, 2020
Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab
Narek Shaverdian, Maria Thor, Annemarie F Shepherd, et al.
Cancer Immunology Research
|
July 12, 2018
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
Fernando C Santini, Hira Rizvi, Andrew J Plodkowski, et al.
Page
of 18